Pharmalot… Pharmalittle… Good Morning

Good morning, folks, and how are you today? A spot of snow has descended on the frosty Pharmalot corporate campus, where we have dusted off the official Pharmalot limousine that chauffeurs the short people to the schoolhouses. As usual, the great morning rush is under way. We have a feeling you can relate. So time to get started. Grab a cup of stimulation and attack your to-do list before it attacks you. Here are some fresh tidbits and, of course, we hope you have a meaningful day. Stay in touch… A Key Trial For A Tuberculosis Vaccine Fails (Reuters) Sanofi Says EU Approves Zaltrap For Bowel Cancer (Reuters) Glaxo Spends $900M To Raise Stake In Indian Consumer Unit (The Guardian) Alnylam Licenses RNAi Cholesterol Drugs To Medicines Company (GENE News) Idenix Halts Developments Of Two Hepatitis C Treatments (Bloomberg News) Fidelity Pushes Endo Health To Sell (Bloomberg News) FDA Approves Generic Doxil To Combat Shortage (Regulatory Focus) falling snow pic thx to mdid on flickr
Source: Pharmalot - Category: Pharma Commentators Authors: Tags: Uncategorized Alnylam Cholesterol Doxil Endo Health Solutions FDA GlaxoSmithKline Heptitis C Idenix Pharmaceuticals Medicines Company RNAi Sanofi TB Tuberculosis Vaccines Zaltrap Source Type: blogs